Health economic evaluation of a vaccine for the prevention of herpes zoster (shingles) and post-herpetic neuralgia in adults in Belgium

References

• Miller E, Marshall R, Vurdien JE. Epidemiology, outcome and control of varicella-zoster virus infection. Rev Med Microbiol 1993;4:222-230
   Google Scholar
• Cunningham AL, Dworkin RH. The management of post-herpetic neuralgia. Br Med J 2000;321:778-779
   PubMed Web of Science ®Google Scholar
• Brisson M, Edmunds WJ, Law B, et al. Epidemiology of varicella zoster virus infection in Canada and the United Kingdom. Epidemiol Infect 2001;127:305-314
   PubMed Web of Science ®Google Scholar
• Yawn BP, Saddier P, Wollan PC, et al. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc 2007;82:1341-1349
   PubMed Web of Science ®Google Scholar
• Johnson R, McElhaney J, Pedalino B, et al. Prevention of herpes zoster and its painful and debilitating complications. Int J Infect Dis 2007;11:S43-48
   PubMed Web of Science ®Google Scholar
• Harpaz R, Ortega-Sanchez IR, Seward JF. Prevention of herpes zoster - Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2008;57:1-40
   PubMedGoogle Scholar
• Opstelten W, Mauritz JW, de Wit NJ, et al. Herpes zoster and postherpetic neuralgia: incidence and risk indicators using a general practice research database. Fam Pract 2002;19:471-475
   PubMed Web of Science ®Google Scholar
• Schmader KE. Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy. Clin J Pain 2002;18:350-354
   PubMed Web of Science ®Google Scholar
• Johnson RW, Wasner G, Saddier P, et al. Postherpetic neuralgia: epidemiology, pathophysiology and management. Expert Rev Neurother 2007;7:1581-1595
   PubMedGoogle Scholar
• Hope-Simpson RE. Postherpetic neuralgia. J R Coll Gen Pract 1975;25:571-575
   PubMedGoogle Scholar
• Schmader K, Gnann JW Jr, Watson CP. The epidemiological, clinical, and pathological rationale for the herpes zoster vaccine. J Infect Dis 2008;197:S207-215
   PubMed Web of Science ®Google Scholar
• Schmader K. Herpes zoster in the elderly: issues related to geriatrics. Clin Infect Dis 1999;28:736-739
   PubMed Web of Science ®Google Scholar
• Volpi A, Gatti A, Pica F, et al. Clinical and psychosocial correlates of post-herpetic neuralgia. J Med Virol 2008;80:1646-1652
   Google Scholar
• Goh CL, Khoo L. A retrospective study of the clinical presentation and outcome of herpes zoster in a tertiary dermatology outpatient referral clinic. Int J Dermatol 1997;36:667-672
   PubMed Web of Science ®Google Scholar
• Chidiac C, Bruxelle J, Daures JP, et al. Characteristics of patients with herpes zoster on presentation to practitioners in France. Clin Infect Dis 2001;33:62-69
   PubMed Web of Science ®Google Scholar
• Schmitt S, Weinke T, Edte A, et al. Herpes zoster and post-herpetic neuralgia seriously impact patients' quality of daily life. 19th IAGG World Congress of Gerontology and Geriatrics (IAGG). Paris, France, July 5-9, 2009 (Abstract)
   Google Scholar
• Katz J, Cooper EM, Walther RR, et al. Acute pain in herpes zoster and its impact on health-related quality of life. Clin Infect Dis 2004;39:342-348
   PubMed Web of Science ®Google Scholar
• Oster G, Harding G, Dukes E, et al. Pain, medication use, and health-related quality of life in older persons with postherpetic neuralgia: results from a population-based survey. J Pain 2005;6:356-363
   PubMed Web of Science ®Google Scholar
• Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005;352:2271-2284
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Prevention of Herpes Zoster. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2008;57
   Google Scholar
• Advisory Committee on Immunization Practices (ACIP). Recommended Adult Immunization Schedule – United States, October 2007-September 2008. 2010
   Google Scholar
• Austrian Superior Sanitary Council, Vaccination Committee March 2nd, 2010. http://www.bmg.gv.at/cms/site/attachments/1/4/0/CH0780/CMS1038913010412/impfplan_2010_korr_maerz.pdf
   Google Scholar
• Cleemput I, van Wilder P, Vrijens F. Guidelines for pharmacoeconomic evaluations in Belgium. Brussels: KCE reports 78 C, 2008
   Google Scholar
• Weinstein MC, O'Brien B, Hornberger J. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices – Modeling Studies. Value Health 2003;6:9-17
   PubMed Web of Science ®Google Scholar
• Nagasako EM, Johnson RW, Griffin DR, et al. Rash severity in herpes zoster: Correlates and relationship to postherpetic neuralgia. J Am Acad Dermatol 2002;46:834-839
   PubMed Web of Science ®Google Scholar
• Caekelbergh K, Lamotte M, Muchada JP. Management of herpes zoster and post-herpetic neuralgia in Belgium: a cost of illness study. 11th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Athens, Greece (Abstract)
   Google Scholar
• Sabbe M, Van Casteren V. Netwerk van Huisartsenpeilpraktijken, Wetenschappelijk Instituut voor Volksgezondheid, 2008. Persoonlijke mededeling, 2008
   Google Scholar
• Sentinel General Practitioners - Scientific Institute of Public Health of Belgium. http://www.iph.fgov.be/epidemio/epien/index10.htm. 2010
   Google Scholar
• Gauthier A, Breuer J, Carrington D, et al. Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom. Epidemiol Infect 2008;137:38-47
   PubMed Web of Science ®Google Scholar
• Statistics Belgium. (2008). Belgian population data 01/01/2006. 2010
   Google Scholar
• Gilderman LI, Lawless JF, Nolen TM, et al. A double-blind, randomized, controlled, multicenter safety and immunogenicity study of a refrigerator-stable formulation of Zostavax®. Clin Vaccine Immunol 2008;15:314-319
   PubMed Web of Science ®Google Scholar
• Kerzner B, Murray AV, Cheng E, et al. Safety and immunogenicity profile of the concomitant administration of Zostavax and inactivated influenza vaccine in adults aged 50 and older. J Am Geriatr Soc 2007;55:1499-1507
   PubMed Web of Science ®Google Scholar
• Schmader K, Oxman MN, Levin M. Persistence of zoster vaccine efficacy. Poster presented at the 48th annual ICAAC/IDSA 46th annual meeting, Washington DC, USA, 25-28 October. Poster number G-409 (Abstract)
   Google Scholar
• Szende A, Williams A. Measuring self-reported population health: an international perspective based on EQ-5D. Budapest, Hungary: SpringMed Publishing Limited, 2004
   Google Scholar
• Cleemput I, Kind P, Kesteloot K. Rescaling social preference data: implications for modelling. In: Kind P, Macran S, eds. 19th Plenary Meeting of the EuroQol Group Discussion Papers York: Centre for Health Economics, University of York, 2004:13-123
   Google Scholar
• McDermott AM, Toelle TR, Rowbotham DJ. The burden of neuropathic pain: results from a cross-sectional survey. Eur J Pain 2006;10:127-135
   PubMed Web of Science ®Google Scholar
• Statistics Belgium (2008). Employment rates 2007/2004. 2008
   Google Scholar
• SECUREX Social Management. (2004). Het Absenteisme in Belgie 2004. Kosten, benchmarks, medische redenen en personeelstevredenheid, 2004
   Google Scholar
• Rodriguez MJ, Diaz S, Vera-Llonch M. Cost-effectiveness analysis of pregabalin versus gabapentin in the management of neuropathic pain due to diabetic polyneuropathy or post-herpetic neuralgia. Curr Med Res Opin 2007;23:2585-2596
   PubMed Web of Science ®Google Scholar
• Edmunds WJ, Brisson M, Rose JD. The epidemiology of herpes zoster and potential cost-effectiveness of vaccination in England and Wales. Vaccine 2001;19:3076-3090
   PubMed Web of Science ®Google Scholar
• Pellissier JM, Brisson M, Levin MJ. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Vaccine 2007;25:8326-8337
   PubMed Web of Science ®Google Scholar
• Bala MV, Wood LL, Zarkin GA. Valuing outcomes in health care: a comparison of willingness to pay and quality-adjusted life-years. J Clin Epidemiol 1998;51:667-676
   PubMed Web of Science ®Google Scholar
• Coplan PM, Schmader K, Nikas A, et al. Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: adaptation of the brief pain inventory. J Pain 2004;5:344-356
   PubMed Web of Science ®Google Scholar
• van Hoek AJ, Gay N, Melegaro A, et al. Estimating the cost-effectiveness of vaccination against herpes zoster in England and Wales. Vaccine 2009;27:1454-1467
   PubMed Web of Science ®Google Scholar
• Dworkin RH, Gnann JW Jr, Oaklander AL, et al. Diagnosis and assessment of pain associated with herpes zoster and postherpetic neuralgia. J Pain 2008;9:S37-44
   PubMed Web of Science ®Google Scholar